World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 19 March 2012
Main ID:  EUCTR2006-006522-25-GR
Date of registration: 04/06/2007
Prospective Registration: Yes
Primary sponsor: CSL Behring AG
Public title: A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)
Scientific title: A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)
Date of first enrolment: 08/01/2008
Target sample size: 28
Recruitment status: Authorised-recruitment may be ongoing or finished
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no Randomised: Open: Single blind: Double blind: Parallel group: Cross over: Other: If controlled, specify comparator, Other Medicinial Product: Placebo: Other:  
Countries of recruitment
Belgium Germany Greece Italy Spain United Kingdom
Key inclusion & exclusion criteria
Inclusion criteria:
Written informed consent, age-adapted· Male or female ages 1 to 70 years
Diagnosis of primary immunodeficiency o CVID as defined by PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies)o XLA
No prior immunoglobulin treatment
IgG level of <500 mg/dL at screening
Women of childbearing potential must use medically approved contraception and must have a negative urine pregnancy test at screening
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
Evidence of serious infection between screening and Day 1 (day of first Vivaglobin infusion)
Bleeding disorders that require medical treatments (e.g. hemophilia)
Any medical disorder causing secondary immune disorders, autoimmune neutropenia, or a clinically significant defect in cell mediated immunity
Hypoalbuminemia, protein-losing enteropathies, and nephropathy with proteinuria· Lymphoprolipherative disease (i.e. lymphoma)
Evidence for bronchiectasis
Known allergic reaction to blood products
Pregnant or breast-feeding females or females planning to become pregnant during the course of the study. Women who have become pregnant during the course of the study have to be withdrawn
Participation in a study with an investigational product within 3 months prior to enrollment
Known or suspected HIV infection, acute hepatitis or clinically active chronic hepatitis
ASAT or ALAT concentration > 2.5 times the UNL·
Creatinine concentration > 1.5 times the UNL
Any condition that is likely to interfere with evaluation of the study drug or satisfactory conduct of the trial

Age minimum:
Age maximum:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Patients with PID diseases as Common Variable Immunodeficiency (CVID) or X-linked agammaglobulinemia ( XLA), age 1 to 70 years
MedDRA version: 8.1 Level: LLT Classification code 10010112 Term: Common variable immunodeficiency

Trade Name: Vivaglobin
Product Name: Vivaglobin
Pharmaceutical Form: Cutaneous solution
INN or Proposed INN: immune globulin subcutaneous (human)
Current Sponsor code: CE1200
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 160-

Primary Outcome(s)
Main Objective: The study is designed to assess the efficacy and safety of Vivaglobin in patients with PID who have not received prior immunoglobulin treatment
Primary end point(s): The primary objective of this trial is to show an increase in the total serum IgG trough level to = 500 mg/dL on study Day 12. For that purpose the total serum IgG trough level will be measured on Day 12, i.e. 7 days after administration of the last loading dose of 100 mg/kg Vivaglobin on Day 5.
The primary efficacy endpoint consists of the proportion of patients achieving IgG levels =500 mg/dL on Day 12.
Secondary Objective:
Secondary Outcome(s)
Secondary ID(s)
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history